Pfizer Inc. slumped after Paxlovid, its pill for treating COVID-19, failed to show benefit as a preventive therapy in a trial. Paxlovid is poised to become one of the fastest-selling drugs of all time, with $24 billion in projected 2022 sales, according to analytics group Airfinity Ltd. Pfizer has also reaped billions in global sales … Continue reading Pfizer Falls as COVID-19 Pill Fails in Preventive Therapy Trial: Data must have been really bad – Dr. Pierre Kory